These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 27895336)
21. Philippines joins other developing countries in limiting prices of drugs. Bland B BMJ; 2009 Aug; 339():b3151. PubMed ID: 19651688 [No Abstract] [Full Text] [Related]
22. TRIPS, pharmaceuticals, developing countries, and the Doha "solution". Sykes AO Chic J Int Law; 2002; 3(1):47-68. PubMed ID: 15709299 [No Abstract] [Full Text] [Related]
23. Seeking truer measures of success: Moving toward more rigorous evaluations of industry-led access to medicines programs. Ramirez CL; Gajeelee A; Desharnais B; Sherman J; Waters D J Glob Health; 2021 May; 11():03062. PubMed ID: 34055323 [No Abstract] [Full Text] [Related]
24. [Drug shortage--cause and prevention]. Madsen S; Claesson U; Wesenberg GR; Endresen M; Walter AB Tidsskr Nor Laegeforen; 2012 Oct; 132(19):2154-5. PubMed ID: 23076482 [No Abstract] [Full Text] [Related]
25. Getting new drugs to market: how individuals could do this without leaving their desks. Collier J BMJ; 2006 Dec; 333(7582):1315-7. PubMed ID: 17185722 [No Abstract] [Full Text] [Related]
27. Public-private partnerships: new ways to discover, develop and deliver drugs for tropical diseases. Hentschel CC Southeast Asian J Trop Med Public Health; 2004; 35 Suppl 2():1-4. PubMed ID: 15906625 [No Abstract] [Full Text] [Related]
28. India: access to affordable drugs and the right to health. Grover A; Citro B Lancet; 2011 Mar; 377(9770):976-7. PubMed ID: 21227487 [No Abstract] [Full Text] [Related]
29. Improving Global Access to State of the Art Practice Information. Gilada TI; Baheti AD; Green DE J Am Coll Radiol; 2016 Sep; 13(9):1156-7. PubMed ID: 27451117 [No Abstract] [Full Text] [Related]
30. Some questions about the moral responsibilities of drug companies in developing countries. Brock DW Dev World Bioeth; 2001 May; 1(1):33-7. PubMed ID: 12870506 [No Abstract] [Full Text] [Related]
31. The UK House of Commons report on the influence of the pharmaceutical industry: lessons for equitable access to medicines in Australia. Faunce TS; Tomossy GF Monash Bioeth Rev; 2005 Apr; 24(2):38-42. PubMed ID: 16208881 [TBL] [Abstract][Full Text] [Related]
32. Looking inward: regional parallel trade as a means of bringing affordable drugs to Africa. Buckely M Seton Hall Law Rev; 2011; 41(2):625-69. PubMed ID: 21739760 [No Abstract] [Full Text] [Related]
34. Access to essential drugs. Dev World Bioeth; 2001 Nov; 1(2):89-92. PubMed ID: 12870517 [No Abstract] [Full Text] [Related]
35. Risks and benefits of importing prescription medications from lower-income countries. Dhalla IA; Detsky AS JAMA; 2008 Sep; 300(12):1453-5. PubMed ID: 18812537 [No Abstract] [Full Text] [Related]
36. MeTA: a welcome force for access to medicines. Lancet; 2008 May; 371(9626):1724. PubMed ID: 18502276 [No Abstract] [Full Text] [Related]
37. South Africa's moral victory. Lancet; 2001 Apr; 357(9265):1303. PubMed ID: 11343727 [No Abstract] [Full Text] [Related]
38. An audience with... Victoria G. Hale. Hale VG Nat Rev Drug Discov; 2005 Nov; 4(11):878. PubMed ID: 16299916 [No Abstract] [Full Text] [Related]
39. Trans-Pacific Partnership Provisions in Intellectual Property, Transparency, and Investment Chapters Threaten Access to Medicines in the US and Elsewhere. Baker BK PLoS Med; 2016 Mar; 13(3):e1001970. PubMed ID: 26954325 [TBL] [Abstract][Full Text] [Related]
40. Freebies for subject 641: a discussion of the ethical prospect of providing drug trial subjects with post-trial access to the drug tested--a Canadian perspective. Hutt LE Health Law J; 1998; 6 Spec No():169-87. PubMed ID: 14746066 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]